重度支气管哮喘给予噻托溴铵并沙美特罗的效果评价

Effect evaluation of the severe bronchial asthma treated with ammonium bromide and Shah Mette Lo

目的:评析重度支气管哮喘患者给予噻托溴铵并沙美特罗联合治疗的临床效果。方法:现以随机对照研究的方式将96例重度支气管哮喘患者划分为对照组与试验组,每组各48例,且均贯彻支气管哮喘的基线治疗,对照组在此基础上施以沙美特罗氟替卡松粉大剂量冲击吸入治疗,试验组则以常规剂量吸入治疗同时采用噻托溴铵粉吸入治疗,疗程为6个月。评估比较两组临床疗效,并测定对比两组患者治疗前后肺功能指标、FEV1提升绝对值、生活质量评分等的变化情况,同时统计两组治疗期间哮喘急性发作次数。结果:试验组的临床总有效率为93.8%,相较于对照组的68.8%,差异有统计学意义(P<0.05);两组治疗后FEV1、FEV1%、PEF、FVC与FEV1/FVC等肺功能指标均有所改善,试验组的改善幅度更大,差异有统计学意义(P<0.05);两组治疗前后FEV1提升绝对值、生活质量评分等均显著改善,而试验组的改善幅度显著更大,差异有统计学意义(P<0.05),另两组治疗期间哮喘急性发作次数差异无统计学意义(P>0.05)。结论:重度支气管哮喘给予噻托溴铵并沙美特罗联合治疗有助于改善患者的肺功能,优化患者生活质量,并减少哮喘的急性发作次数,疗效显著,值得临床重视与采纳。

Objective Comment on severe asthma patients given tiotropium and salmeterol clinical effects of combination therapy. Method 96 patients with severe bronchial asthma were divided into control group 48 cases and experimental group 48 cases. The two groups were treated with FEV1 ,and the control group was treated with conventional dose of treatment. The clinical efficacy was evaluated by comparing the two groups. The clinical efficacy, pulmonary function index before and after treatment, FEV1 to enhance the absolute value,quality of life score were compared with the two groups. Results the total effective rate was 93. 8% in the experimental group, the experimental group was improved significantly （ P 〈 0. 05 ） , the FEV1 % , PEF, FEV1/FVC, FVC and FEVL were significantly improved （ P 〈 0. 05 ）, while the improvement of the experimental group was significantly greater （ P 〈 0. 05 ）,while the other two groups had no significant differences （ P 〉 0. 05 ）. Conclusion For the patients with severe bronchial asthma give Sai tiotropium and salmeterol combination therapy is helpful to improve the pulmonary function of patients, optimize patient quality of life, and reduce asthma exacerbations, significant effect ,worthy of clinical attention and adoption.